Molecular and Clinical Evidence for an ARMC5 Tumor Syndrome: Concurrent Inactivating Germline and Somatic Mutations Are Associated With Both Primary Macronodular Adrenal Hyperplasia and Meningioma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
CONTEXT: Primary macronodular adrenal hyperplasia (PMAH) is a rare cause of Cushing's syndrome, which may present in the context of different familial multitumor syndromes. Heterozygous inactivating germline mutations of armadillo repeat containing 5 (ARMC5) have very recently been described as cause for sporadic PMAH. Whether this genetic condition also causes familial PMAH in association with other neoplasias is unclear. OBJECTIVE: The aim of the present study was to delineate the molecular cause in a large family with PMAH and other neoplasias. PATIENTS AND METHODS: Whole-genome sequencing and comprehensive clinical and biochemical phenotyping was performed in members of a PMAH affected family. Nodules derived from adrenal surgery and pancreatic and meningeal tumor tissue were analyzed for accompanying somatic mutations in the identified target genes. RESULTS: PMAH presenting either as overt or subclinical Cushing's syndrome was accompanied by a heterozygous germline mutation in ARMC5 (p.A110fs*9) located on chromosome 16. Analysis of tumor tissue showed different somatic ARMC5 mutations in adrenal nodules supporting a second hit hypothesis with inactivation of a tumor suppressor gene. A damaging somatic ARMC5 mutation was also found in a concomitant meningioma (p.R502fs) but not in a pancreatic tumor, suggesting biallelic inactivation of ARMC5 as causal also for the intracranial meningioma. CONCLUSIONS: Our analysis further confirms inherited inactivating ARMC5 mutations as a cause of familial PMAH and suggests an additional role for the development of concomitant intracranial meningiomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MutationTaster evaluates disease-causing potential of sequence alterations
Schwarz, J. M., Rödelsperger, C., Schuelke, M., & Seelow, D. (2010) · Nature Methods · doi:10.1038/nmeth0810-575 · Cited by 2,975
Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays
Drmanac, R., Sparks, A. B., Callow, M. J., Halpern, A. L., Burns, N. L., Kermani, B. G., Carnevali, P., Nazarenko, I., Nilsen, G. B., Yeung, G., et al. (2010) · Science · doi:10.1126/science.1181498 · Cited by 1,212 · cited 1×
“DNA samples were sequenced by Complete Genomics (Complete Genomics Inc) (39).”
MethodUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458 · cited 1×
“Furthermore, 24-hour urine samples were collected for detailed assessment of glucocorticoid production by gas chromatography/mass spectrometry as previously described (38); this included measurement of free cortisol and the total sum of glucocorticoid metabolites (free cortisol, tetrahydrocortisol, 5 -tetrahydrocortis…”
MethodSelf-citationARMC5 Mutations in Macronodular Adrenal Hyperplasia with Cushing's Syndrome
Assié, G., Libé, R., Espiard, S., Rizk-Rabin, M., Guimier, A., Luscap, W., Barreau, O., Lefèvre, L., Sibony, M., Guignat, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304603 · Cited by 395
Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome.
Lacroix, A., Hamet, P., & Boutin, J.-M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412104 · Cited by 244 · cited 1×
“These primarily aberrant G protein-coupled receptors showing hyperactivity or paradoxical stimulation include ectopic receptors for glucose-dependent insulinotropic peptide (22, 23), catecholamines (24), LH/human chorionic gonadotrophin (25), and IL-1 via type I IL-1 receptors (26) as well as eutopic receptors for vas…”
BackgroundPropranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing's syndrome.
Lacroix, A., Tremblay, J., Rousseau, G., Bouvier, M., & Hamet, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711133372004 · Cited by 204
Faucz, F. R., Zilbermint, M., Lodish, M. B., Szarek, E., Trivellin, G., Sinaii, N., Berthon, A., Libé, R., Assié, G., Espiard, S., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4280 · Cited by 166 · cited 2×
“Follow-up studies confirmed ARMC5 germline mutations in the context of PMAH with CS (37), and the simultaneous occurrence of germline and somatic ARMC5 mutations in a large Brazilian family further substantiated the role of this putative tumor suppressor gene for the pathogenesis of PMAH (32).”
BackgroundARMC5 Mutations Are a Frequent Cause of Primary Macronodular Adrenal Hyperplasia
Alencar, G. A., Lerario, A. M., Nishi, M. Y., Mariani, B. M. D. P., Almeida, M. Q., Tremblay, J., Hamet, P., Bourdeau, I., Zerbini, M. C. N., Pereira, M. A. A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4237 · Cited by 162 · cited 10×
“In their series 24-hour urinary free (or total) cortisol excretion was above the reference range in only 2 of 14 diagnosed PMAH patients and similarly, late-night salivary cortisol was increased in only 4 of 15 patients with PMAH (32).”
BackgroundResultInfluentialWnt/β-catenin signalling in adrenal physiology and tumour development
Berthon, A., Martinez, A., Bertherat, J., & Val, P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.009 · Cited by 125
Rothenbuhler, A., Horvath, A., Libé, R., Faucz, F. R., Fratticci, A., Raffin Sanson, M. L., Vezzosi, D., Azevedo, M., Levy, I., Almeida, M. Q., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04366.x · Cited by 96
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Espiard, S., Drougat, L., Libé, R., Assié, G., Perlemoine, K., Guignat, L., Barrande, G., Brucker-Davis, F., Doullay, F., Lopez, S., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4204 · Cited by 196
“003 <10 60% 92% 53% 10 to 15 30% 8% 34% >15 9% 0% 12% UFC (% of increase above the upper limit of the normal) $$ 204 [11–2433] 355 [11–1626] 167 [16–2433] 0.”
InfluentialBourdeau, I., El Ghorayeb, N., Gagnon, N., & Lacroix, A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0296 · Cited by 98
Multiple aberrant hormone receptors in Cushing’s syndrome
Ghorayeb, N. E., Bourdeau, I., & Lacroix, A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0200 · Cited by 90
Metadata
- Authors
- Elbelt, U., Trovato, A., Kloth, M., Gentz, E., Finke, R., Spranger, J., Galas, D., Weber, S., Wolf, C., König, K., Arlt, W., Büttner, R., May, P., Allolio, B., & Schneider, J. G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-01
- Volume
- 100
- Issue
- 1
- Pages
- E119-E128
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2139179696
- Cited by
- 115
- References
- 10
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.